Shweta Maniar Biography and Net Worth

Director of RxSight

Ms. Maniar joined our Board in December 2021, at which time she was nominated to serve as a member of the Governance Committee. Since July 2018, Ms. Maniar has served as Global Leader, Healthcare & Life Sciences Solutions & Strategy at Google, where she leads vision, strategy, and execution of Google Cloud's industry product strategy and go-to-market model. Prior to joining Google (Alphabet, Inc.) (NASDAQ:GOOG), from November 2013 to June 2018, Ms. Maniar contributed as an executive at Genentech, where she led market growth strategies relevant to technology accelerators for therapies and diagnostics. For more than a year previously, she served as Director for the Center of Minimally Invasive Therapeutics at Summa Health. Earlier in her career, Ms. Maniar spent several years in a research capacity at the Cleveland Clinic and the Austen BioInnovation Institute in Akron, where she was primarily focused on medical devices and minimally invasive therapeutics. She currently serves on the board of directors of Orthofix Medical Inc. (NASDAQ:OFIX). Ms. Maniar holds a B.A. in Economics from the University of California, San Diego.

What is Shweta Maniar's net worth?: The estimated net worth of Shweta Maniar is at least $120,047.58 as of January 22nd, 2025. Maniar owns 7,383 shares of RxSight stock worth more than $120,048 as of April 6th. This net worth evaluation does not reflect any other investments that Maniar may own. Learn More about Shweta Maniar's net worth.
How do I contact Shweta Maniar?: The corporate mailing address for Maniar and other RxSight executives is , , . RxSight can also be reached via phone at 949-521-7830 and via email at ir@rxsight.com. Learn More on Shweta Maniar's contact information.
Has Shweta Maniar been buying or selling shares of RxSight?: Shweta Maniar has not been actively trading shares of RxSight over the course of the past ninety days. Most recently, Shweta Maniar sold 3,519 shares of the business's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a transaction totalling $108,631.53. Following the completion of the sale, the director now directly owns 7,383 shares of the company's stock, valued at $227,913.21. Learn More on Shweta Maniar's trading history.
Who are RxSight's active insiders?: RxSight's insider roster includes Julie Andrews (Director), Juliet Bakker (Director), Jesse Corley (Director), Tamara Fountain (Director), Ilya Goldshleger (Insider), Ilya Goldshleger (Insider), M Kurtz (CEO), William Link (Director), Shweta Maniar (Director), Shelley Thunen (CFO), Robert Warner (Director), and Eric Weinberg (Insider). Learn More on RxSight's active insiders.
Are insiders buying or selling shares of RxSight?: In the last year, RxSight insiders bought shares 2 times. They purchased a total of 12,554 shares worth more than $549,098.81. In the last year, insiders at the sold shares 28 times. They sold a total of 160,951 shares worth more than $8,269,376.44. The most recent insider tranaction occured on March, 12th when Director Tamara Fountain sold 7,000 shares worth more than $179,970.00. Insiders at RxSight own 9.4% of the company. Learn More about insider trades at RxSight.
Information on this page was last updated on 3/12/2025.

Shweta Maniar Insider Trading History at RxSight

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2025	Sell	3,519	$30.87	$108,631.53	7,383
11/26/2024	Sell	3,782	$45.88	$173,518.16	10,902
1/18/2024	Sell	6,399	$45.72	$292,562.28	12,130
8/29/2023	Sell	4,292	$28.06	$120,433.52	24,947

Shweta Maniar Buying and Selling Activity at RxSight

RxSight Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $16.26

$15.01

$16.56

50 Day Range

MA: $28.12

$16.21

$34.26

2 Week Range

Now: $16.26

$14.37

$66.54

Volume

2,105,935 shs

Average Volume

582,609 shs

Market Capitalization

$658.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26